Brexit Forces Biggest Insulin Supplier to Turn to the Skies
- Danish drugmaker Novo books space on planes, boosts stockpiles
- Pharma lobby group sees ‘immediate threats to patient safety’
A high speed production line of insulin at a Novo Nordisk factory.
Photographer: Jean-Francois Monier/AFP via Getty Images
This article is for subscribers only.
Bracing for a chaotic Brexit, the world’s biggest maker of insulin has reserved space on airplanes and plans to boost stockpiles further to ensure diabetes patients in the U.K. don’t run out of the life-saving medicine.
Novo Nordisk A/S, the Danish drugmaker, booked some air-freight slots to prepare for the possibility of significant border delays, Pinder Sahota, its U.K. general manager, said in an interview. The company also is aiming to increase stockpiles of insulin to as much as 18 weeks by the end of March, from seven weeks typically.